Chapter 01

Our Company

Value Creation Model

Olympus’ Value Creation Model
OUR PURPOSE

Social Outcome

Making people’s lives healthier, safer
and more fulfilling

StrengthStrong position built on basis ofrelationships of trust with customers	Global market share for gastrointestinal endoscopes
approximately 70%	Training for doctors conducted around the world	Entered emerging markets ahead of other companies
and built relationships of trust with doctors

Providing value to patients, countries, andsociety through our customers
Patients

Strategy ontributing to the health of peopleCaround the worldImproving patient outcomes by elevating
the standard of care in target diseases
based on early diagnosis and minimallyinvasive treatments

Corporate Strategy
Transforming into a Truly GlobalMedtech Company
Realization of corporate culture and structurethat enables sustainable growth	Have built relationships of trust in Chinese market for about
50 years, since normalization of diplomatic relations between
Japan and China in 1972	Established representative office in Singapore in 1975 eedback onF
product improvementsand requests

Global and robust management foundation

Diverse human resources that possesshigh expertise	Aiming to become a global medtech company, hiring
highly specialized and talented people for global positions	To further grow mainly in the Therapeutic Solutions Business,
set up a specialized business development team in the U.S.,
hired talented people, and carried out M&A	Percentage of foreign management roles globally:
approximately 51%*3	To strengthen implementation skills, approximately 6,000
employees participated in training, and approximately 4,500
people participated in the Global Communication Skill
Strengthening Program*210Olympus Integrated Report 2022

Colonoscopies
performed worldwide*4100
Diseases orconditions treated*5

Customers
Relationshipsof trust built bycollaboratingwith customers(Medical institutions, research institutions, manufacturing industry, etc.)

 ontributing to improvements in efficiency of medical care andC
its economic outcomes through early diagnosis andminimally invasive treatments
Contributing to biological/medical research as well as pathology researchContributing to industrial efficiency and improvements in inspection qualitytoCountries/SocietyusTechnological capabilities that produce
high-quality and advanced products	Selected as one of the top 100 most innovative companies
in the world 10 times	Olympus Group’s approximately 20,000 patents*2 tobuild a high-quality IP portfolio	Strong know-how and optical technology built up since
the Company’s founding	Manufacturing techniques that realize high-mix,
low-volume production

 roviding products
Pthat help improve
patient outcomes bymeeting abundant needs
Support for proceduredevelopment

millionmer

an dv a lue	Approximately 17 training centers with the aim ofproviding training opportunities for healthcare professionals	Build an industry-leading service network among
the world’s medical device companies	Established a global headquarters for the TherapeuticSolutions Business in the U.S.	Credit ratings: A (R&I), BBB+ (S&P), Baa2 (Moody’s)	Approximately 990 dialogues with institutional investors
and securities analysts*150

F o cusinngothec ontributing to limiting medical expenses through earlyC
diagnosis and minimally invasive treatments
Contributing to the future of medicine
Contributing to safety and security in everyday lives

See page 41 for Medical Business Direction

Six Important ESG Areas
1. Corporate governance
2. Economic sustainability
3. Product sustainability

4. Environment
5. People
6. Society

Our Materiality
Healthcare access and outcomes
Compliance, product quality and safety
Responsible supply chain
Diversity and inclusion
Carbon neutral society and circular economy

Financial KPIs

5-6%

Annual average revenue
growth rate

> 20 %
Operating margin*6*1 Fiscal year 2022
*2 As of March 2022
*3 The percentage within global senior management as of July 1, 2022
*4	Numbers come from the Company’s research. Numbers of the US, Canada, Germany, France, Italy, Spain, the UK, Poland, Japan, China, South Korea, Australia, India, and Russia.
As of 2019
*5 Olympus has versatile medical devices with the ability to treat approximately 100 diseases or conditions as of March 2022.
*6 Operating Profit excludes “Other income/expenses.” adjustments are made for the impact of exchange rate fluctuations; actual exchange rates are used.

11